Download View RNA

Figure 5: IGFBP-3 mRNA expression in FFPE human liver tissue samples detected using radioactivity and
QuantiGene® ViewRNA Assay.
Taken together, these results highlight the specificity and sensitivity of the bDNA method for in situ
hybridization. Furthermore, this method has considerably improved the workflow, such that the time
to obtain results has been significantly reduced compared to traditional methods.
Please visit www.panomics.com to learn more about the QuantiGene® ViewRNA Assay.
References
1. Canales R. D., et al. Evaluation of DNA microarray results with quantitative gene expression
platforms. Nature Biotechnology 24(9):1115-1122 (2006).
2. Zhao J., et al. Secreted antibody/granzyme B fusion protein stimulates selective killing of HER2overexpressing tumor cells. Journal of Biological Chemistry 279(20):21343–21348 (2004).
3. Yu C. J., et al. Selective proapoptotic activity of a secreted recombinant antibody/AIF fusion protein
in carcinomas overexpressing HER2. Gene Therapy 13(4):313–320 (2006).
Affymetrix, Inc. +1-888-362-2447Affymetrix UK Ltd. +44-(0)1628-552550Affymetrix Japan K.K. +81-(0)3-6430-4020
Panomics Products +1-877-PANOMICS www.panomics.comUSB Products +1-800-321-9322 www.usb.affymetrix.com
www.affymetrix.com Please visit our website for international distributor contact information.
For research use only. Not for use in diagnostic procedures.
P/N WH112 Rev. 1
©2010 Affymetrix, Inc. All rights reserved. Affymetrix®, Axiom™, Command Console®, DMET™, GeneAtlas™, GeneChip®, GeneChip-compatible™, GeneTitan®,
Genotyping Console™, myDesign™, NetAffx ®, Powered by Affymetrix™, Procarta®, and QuantiGene® are trademarks or registered trademarks of Affymetrix, Inc.
Luminex® and xMAP® are registered trademarks of Luminex Corp. All other trademarks are the property of their respective owners.
Page 6 of 6